JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2018. Vol. 63. No. 4. P. 58-62
NUCLEAR MEDICINE
DOI: 10.12737/article_5b83bf207b9b50.21392988
Diagnostic Bone-Seeking Radiopharmaceutical Agent on the Basis of Zoledronic Acid «Rezoscan, 99mTс» Preliminary Results of Comparative Clinic Studies
A.V. Tultaev, V.N. Korsunskiy, A.A. Labushkina, M.V. Zabelin
A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. ; A.V. Tultaev - Senior Researcher, PhD Tech.; V.N. Korsunskiy - Leading Researcher, Dr. Sc. Med., Prof.; A.A. Labushkina - Research Worker, PhD Med.; M.V. Zabelin - Dr. Sc. Med., Prof., Head of Dep.
Abstract
Purpose: Clinical trials involving study of functions, assessment of drug and radiation safety of the radiopharmaceutical drug “Rezoscan, 99mTc” in comparison with the “Technefor, 99mTc”.
Material and methods: Clinical studies of RP “Rezoscan, 99mTc” were carried out using a diagnostic gamma camera Toshiba. The study involved 25 patients: 2 patients diagnosed with prostate cancer, 3 patients diagnosed with cervical cancer, 15 patients diagnosed with breast cancer and 5 patients diagnosed with coronary artery disease without cancer, who underwent osteoscintigraphy to identify osteoporosis foci and who signed an informed consent to participate in the study. To study the functional properties of RP “Rezoscan, 99mTc”, we studied its pharmacokinetics and evaluated the quality of visualization of pathological foci in bone tissue. To assess drug safety the patient was monitored for 15 days with an assessment of acute and delayed reactions to intravenous administration. Radiation safety of the RP was estimated using values of absorbed radiation doses of organs and effective doses to patients [1]. To the same patients the radiopharmaceutical preparations “Rezoscan, 99mTc” and “Technefor, 99mTc” were injected sequentially in one day.
Results: According to the pharmacokinetics study, the accumulation of RP “Rezoscan, 99mTc” in the skeleton in 2 hours reaches 40 % of the administered amount. At the same time, a relatively rapid excretion of the drug from the soft tissues takes place, which makes it possible to clearly visualize the condition of the bone system and to reveal pathological changes with coefficients of differential accumulation (CDA) bone/soft tissues of about 10. Comparative studies of the functional characteristics of RP “Rezoscan, 99mTc” and “Technefor, 99mTc” showed the advantage of the new drug in the early detection of pathological changes in bone tissue with the metastatic skeletal lesion. In all cases in the study with RP “Rezoscan, 99mTc”on scintigrams in 15 patients with a verified diagnosis of breast cancer, the pathological foci of hyperfixation RP, which are typical for metastatic bone lesions, were visualized. In the same patients, examined with the help of the RP “Technefor, 99mTc”, pathological foci in the skeleton were visualized only in 13 cases.
According to the results of studies of patients with RP “Rezoscan, 99mTc” accuracy was 0.8, sensitivity - 0.9, specificity - 0.6. According to the study of patients of the same group with RP “Technefor, 99mTc” defined: the accuracy is 0.8, sensitivity - 0.8 and specificity - 0.4.
Based on the results of monitoring the condition of patients for 15 days, acute and delayed reactions to intravenous administration of the drug were not detected. The estimate of the absorbed radiation dose values of RP “Rezoscan, 99mTc” in organs and tissues of patients, as well as effective doses of irradiation allow us to suggest that the introduced RP activity and patient dose do not go beyond the previously established reference levels.
Conclusions: The radiopharmaceutical “Rezoscan, 99mTc” can be used for the early detection of pathological foci of bone tissue.
Key words: radiopharmaceuticals, zoledronic acid, osteoscintigraphy, “Rezoscan, 99mTc”, “Technefor, 99mTc”
REFERENCES
- ICRP, Publication 106, Radiation Dose to patients from Radiopharmaceuticals; 2007.
- Subramanian G, Agfee JG. A New Complex of Tc for Skeletal Inmaging. Radiology. 1971;99:192-6.
- Rosenhall L, Kaye M. Technetium-99m pyrophosphate kinetics an imaging in metabolic bone Disease. J Nucl Med. 1975;16:33-8.
- Schmitt G, Holmes R, Isitman A. A proposed mechanism for 99mTc-labeled polyphosphate and diphosphonate uptake by human breast tissue. Radiology. 1974;112:733-40.
- Tofe A, Fransis M. In vitro stabilization of a low-tin bon-imaging agent (99mTc-Sn HEDP) by ascorbic acid. J Nucl Med. 1976;17:820-6.
- Subramanian G, Agfee J, et al. Nc-99m-methylendifosphonate a superior agent for skeletal imaging; comparison with other technetium complexes. J Nucl Med. 1975;16:744-51.
- Finding a new osteotropic drugs with technetium-99m based on DTPMPA. The research reports. Institute of Biophysics. Inv. No. b-4388. Moscow; 1983. Russian.
- Cristy M, Eckerman K. Specific absorbed fraction of energy at varicus ages from internal photon sources. ORNL/TM-8391N1-7. Oak Ridge National Laboratory; 1987.
- Asikoglu M, Durak FG. The biodistribution of a therapeutic dose of zoledronic acid labeled with Tc-99m. Appl Radiat Isot. 2009;67(9):1616-21.
- Kasatkin YuN, Vidukov VI. Methods of decision-making in radionuclide diagnostics. Moscow; 1983. Russian.
For citation: Tultaev AV, Korsunskiy VN, Labushkina AA, Zabelin MV. Diagnostic Bone-Seeking Radiopharmaceutical Agent on the Basis of Zoledronic Acid «Rezoscan, 99mTс» Preliminary Results of Comparative Clinic Studies. Medical Radiology and Radiation Safety. 2018;63(4)58-62. Russian. DOI: 10.12737/article_5b83bf207b9b50.21392988
PDF (RUS) Full-text article (in Russian)